Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.

ABSTRACT:

Objective

The present study aimed to assess the long-term safety and tolerability of valsartan in hypertensive children aged 6-17 years, with or without chronic kidney disease (CKD).

Methods

This was an 18-month, open-label, multicentre, prospective study conducted in 150 patients with history of hypertension with or without CKD. The primary endpoint was long-term safety and tolerability of valsartan and valsartan-based treatments, assessed in terms of adverse events (AEs), serious AEs, laboratory measurements, estimated glomerular filtration rate (eGFR), urinalysis and electrocardiogram.

Results

Of 150 enrolled patients, 117 (78%) completed the study. At week 78, a clinically and statistically significant reduction in mean sitting systolic and diastolic blood pressur

SUBMITTER: Lou-Meda R 

PROVIDER: S-EPMC6349801 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature